Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - September 2014


SLAS Short Courses

01 Sep 2014 - 01 Sep 2014 - Manchester, UK



Bookmark and Share


The courses are complementary to the conference program; their objective is to educate people interested in these fields, providing an in-depth understanding of the topic and a comprehensive overview of the key techniques and recent developments. Delivered by distinguished faculty, these courses address a range of timely issues using real-world examples.

Later, in the conference, you can hear from researchers actively involved in these areas about their experiences and how the leading-edge is being explored !

The quality and educational content of SLAS short courses is well recognized and very well respected in our industry, and we are pleased to be partnering with SLAS to deliver these to you.

There is a charge to attend the short-courses, whilst the main Drug Discovery conference on Tue 2nd and Wed 3rd Sept remains free to attend ( please register for each separately ).

COURSE 1 : Introduction to Laboratory Automation

Jonathan Wingfield : AstraZeneca
Malcolm Crook : Peak Analysis & Automation

This introduction to automation course will provide a basic overview of when and how to successfully deploy automation within a laboratory environment. The course is tailored for managers who want to understand the strategic and tactical options for automation deployment. There will be an overview of the principles of automation architecture, infrastructure and laboratory informatics. There is no requirement for a working knowledge of, or experience with, automation.

View / download a full course summary.

COURSE 2 : High Content Screening: Instrumentation, Assay Development, Screening, Image and Data Analysis

Eberhard Krauß : ChemBioCon
Marc Bickle : Head HT-Technology Development Studio, Max Planck Institute of Molecular Cell Biology and Genetics

High-content screening is a powerful technology platform for implementing functional cell-based assays that allow truly multi-parametric analysis in the physiological context of intact cells. This course provides a state-of-the-art overview of the components of HCS (instrumentation, reagents, HC assay development, automated image analysis and multi-parametric data analysis, and data standards) together with some showcases of small molecule and RNAi high-content screens in industry and academia.

A demonstration will be given using the open source software CellProfiler how to analyze early endosomes in HeLa cells. Nuclei, cytosol and endosomes will be segmented and quantified. The resulting data will then be analyzed using the open source software KNIME. Parameters will be tested for normality, normalized and assembled into multiparametric profiles. The profiles will be quantified to estimate phenotypic strength and clustered to determine phenotypes. Both the slides describing the analysis and the pipelines will be made available to course participants to allow them to recreate the workflow in their own laboratories.

View / download a full course summary.

COURSE 3 : Establishing Cell-Based Assays and Implementing 3D Culture Models for screening and drug testing

Terry Riss : Senior Product Specialist, Cell Health, Promega Corporation
Jens Kelm : Insphero

This course will describe developing standard procedures for handling cultured cells to set up cell-based assays, describe techniques for measuring cell health and the mechanisms leading to cytotoxicity, and provide an overview of recent technological advances in 3D culture technologies that enable automation-compatible drug testing with more predictive and biologically relevant assays. Case studies will be presented which provide examples of using 3D model systems for screening and drug testing.

View / download a full course summary.



Further information
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!